Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib
Our findings support the clinical impression of a high incidence of irAEs in bosutinib-treated patients and may lead to an enhanced understanding of bosutinib's safety profile and mechanism of action.
Authors
- Carlo Gambacorti‐Passerini (ORCID: https://orcid.org/0000-0001-6058-515X)
- Elena Tassistro (ORCID: https://orcid.org/0000-0001-5166-7305)
- Laura Antolini (ORCID: https://orcid.org/0000-0003-1040-4191)
- Elena Agostani
Institutions
- Azienda Ospedaliera San Gerardo (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/cam4.70580
- Citations
- 5
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.85